Viiv Hlthcare Company Profile

✉ Email this page to a colleague

VIIV HLTHCARE has twenty-six approved drugs.

There are fifteen US patents protecting VIIV HLTHCARE drugs.

There are five hundred and fifty-eight patent family members on VIIV HLTHCARE drugs in sixty-seven countries and one hundred and eighty-four supplementary protection certificates in eighteen countries.

Subscribe to access the full database, or Sign up for a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	SELZENTRY	maraviroc	SOLUTION;ORAL	208984-001	Nov 4, 2016		RX	Yes	Yes		See Plans and Pricing				See Plans and Pricing
Viiv Hlthcare	TIVICAY PD	dolutegravir sodium	TABLET, FOR SUSPENSION;ORAL	213983-001	Jun 12, 2020		RX	Yes	Yes	8,129,385	See Plans and Pricing	Y	Y		See Plans and Pricing
Viiv Hlthcare	EPZICOM	abacavir sulfate; lamivudine	TABLET;ORAL	021652-001	Aug 2, 2004	AB	RX	Yes	Yes		See Plans and Pricing				See Plans and Pricing
Viiv Hlthcare	TRIUMEQ PD	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET, FOR SUSPENSION;ORAL	215413-001	Mar 30, 2022		RX	Yes	Yes		See Plans and Pricing				See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign up for a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viiv Hlthcare	LEXIVA	fosamprenavir calcium	TABLET;ORAL	021548-001	Oct 20, 2003	6,436,989*PED	See Plans and Pricing
Viiv Hlthcare	TRIUMEQ	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET;ORAL	205551-001	Aug 22, 2014	6,294,540*PED	See Plans and Pricing
Viiv Hlthcare	RETROVIR	zidovudine	INJECTABLE;INJECTION	019951-001	Feb 2, 1990	4,833,130	See Plans and Pricing
Viiv Hlthcare	EPIVIR	lamivudine	TABLET;ORAL	020564-003	Jun 24, 2002	6,180,639*PED	See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	150 mg and 300 mg	➤ Subscribe	2007-10-16
➤ Subscribe	Tablets	150 mg and 300 mg	➤ Subscribe	2011-08-08
➤ Subscribe	Oral Solution	20 mg/ml	➤ Subscribe	2012-12-27
➤ Subscribe	Tablets	150 mg/300 mg	➤ Subscribe	2007-06-26
➤ Subscribe	Tablets	10 mg, 25 mg and 50 mg	➤ Subscribe	2017-08-14
➤ Subscribe	Tablets	300 mg/150 mg/300 mg	➤ Subscribe	2011-03-22
➤ Subscribe	Oral Solution	10 mg/mL	➤ Subscribe	2011-11-22
➤ Subscribe	Tablets	300 mg	➤ Subscribe	2009-01-28
➤ Subscribe	Tablets	700 mg	➤ Subscribe	2012-01-18
➤ Subscribe	Tablets	600 mg/300 mg	➤ Subscribe	2007-09-27
➤ Subscribe	Tablets	600 mg/50 mg/300 mg	➤ Subscribe	2017-08-14

Subscribe to access the full database, or Sign up for a Free Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1419152	CA 2012 00021	Denmark	See Plans and Pricing
1284974	PA2008004,C1284974	Lithuania	See Plans and Pricing	PRODUCT NAME: MARAVIROCUM; REGISTRATION NO/DATE: EU/1/07/418/001 - EU/1/07/418/010, 0070918
1663240	122015000088	Germany	See Plans and Pricing	PRODUCT NAME: KOMBINATION VON RILPIVIRIN ODER EINER THERAPEUTISCH AEQUIVALENTEN FORM DAVON, DIE DURCH DAS GRUNDPATENT GESCHUETZT IST, WIE Z.B EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ VON RILPIVIRIN, EINSCHLIESSLICH DES HYDROCHLORIDSALZES VON RILPIVIRIN, TENOFOVIR, INSBESONDERE TENOFOVIRDISOPROXILFUMARAT, UND EMTRICITABIN; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128
0933372	PA2008006,C0933372	Lithuania	See Plans and Pricing	PRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.